Compare Incyte Corporation (INCY) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Williams-Sonoma, Inc. — how do they compare? Incyte Corporation trades at $117 (market cap $23.11B), while Williams-Sonoma, Inc. trades at $223.2 (market cap $26.30B). The key difference: Incyte Corporation and Williams-Sonoma, Inc. are close in size by market cap, and Williams-Sonoma, Inc. pays a 1.36% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | WSM | |
|---|---|---|
Market Cap | $23.11B | $26.30B |
Sector | Health | Consumer Cyclical |
52-Week High | $118.52 | $240.06 |
52-Week Low | $67.38 | $168.64 |
Enterprise Value | $19.13B | $27.14B |
Dividend Yield | — | 1.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $117.39, up 0.12% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $112.78. The company reported strong Q1 2026 earnings of $1.81 per share, beating expectations, and maintains robust profitability with a net income margin of 26.71%. Recent developments include a collaboration with Halozyme for cancer therapy and positive regulatory updates for Opzelura in Europe.
Outlook remains positive driven by earnings growth and pipeline advancements, though risks include competitive pressures and reliance on key products. The stock offers potential upside to the high target of $140, supported by institutional interest and solid cash flow generation, but investors should monitor execution on upcoming Q2 results.
Williams-Sonoma (WSM) trades at $221.13, down 3.19% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company maintains strong profitability with a 13.81% net margin and 54.01% ROE, though revenue has shown volatility. Recent earnings beats and consistent dividend payments highlight operational strength amid consumer discretionary sector challenges noted in recent financial media coverage.
The outlook is mixed with solid fundamentals and analyst consensus near current price, but risks include consumer spending sensitivity and competitive pressures. Upside potential exists if earnings momentum continues, yet macroeconomic headwinds and sector underperformance pose near-term challenges for shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
